| Symbol | AUTL |
|---|---|
| Name | AUTOLUS THERAPEUTICS PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 191 WOOD LANE,THE MEDIAWORKS, LONDON, W12 7FP, United Kingdom |
| Telephone | +44 2038296230 |
| Fax | — |
| — | |
| Website | https://www.autolus.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001730463 |
| Description | Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The companys clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Additional info from NASDAQ: |
Director BUTITTA CYNTHIA M 🟢 acquired 79.2K shares (2 derivative) of Autolus Therapeutics plc (AUTL) at $1.61 Transaction Date: Jun 29, 2026 | Filing ID: 000097
Read moreAutolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreDirector BONNEY MICHAEL W 🟢 acquired 79.2K shares (2 derivative) of Autolus Therapeutics plc (AUTL) at $1.61 Transaction Date: Jun 29, 2026 | Filing ID: 000091
Read moreAutolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
Read moreNew Form SCHEDULE 13G/A - Autolus Therapeutics plc <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001426156-26-000009 <b>Size:</b> 12 KB
Read moreNew Form SCHEDULE 13G/A - Autolus Therapeutics plc <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001172661-26-002127 <b>Size:</b> 10 KB
Read more